Long acting insulin reaching the phase 3 clinical end point is expected to benefit children and adolescents with type 1 diabetes

Today, Sanofi announced that its long-acting insulin toujeo gla-300 (insulin glargine 300 units / ml) reached the primary end point of non inferiority in the edition junior experiment for children and adolescents (6-17 years old) with type 1 diabetes, compared with toujeo gla-100 (insulin glargine 100 units / ml) The latest data was released at the 45th annual meeting of the international society for children and adolescents diabetes in Boston Type 1 diabetes mellitus is an autoimmune disease in children, which is characterized by immune-mediated loss of β cell function According to statistics, in the United States, one in 300 people under the age of 18 has type 1 diabetes Type 1 diabetes is an insulin-dependent diabetes mellitus Its patients need to deal with the fluctuation of blood glucose frequently Among them, high blood glucose can cause ketosis and ketoacidosis, while hyperhypoglycemia can cause hypoglycemia Managing blood sugar fluctuations is particularly challenging for children and adolescents Toujeo gla-300 is a long-acting insulin with insulin content three times that of standard 1ml insulin (100 units / ml) It was approved by FDA in 2015 Including insulin glargine, the main activity of insulin is to regulate glucose metabolism, through stimulating peripheral glucose uptake, especially the uptake of glucose by skeletal muscle and fat, and through inhibiting the production of liver glucose to achieve the effect of lowering blood glucose ▲ edition junior test results (picture source: reference [1]) The edition junior trial, in patients with type 1 diabetes between the ages of 6 and 17, with HbA1c between 7.5% and 11.0, verified the effectiveness of toujeo gla-300 in reducing HbA1c levels and managing blood glucose fluctuations (incidence of ketosis and hypoglycemia) compared to toujeo gla-100 The toujeo gla-300 group achieved the primary end point of non inferiority in reducing HbA1c levels, and the incidence of ketosis and severe hypoglycemia (< 54 mg / dl) was relatively lower in the group Mr Dietmar Berger, director of global development of Sanofi, said: "globally, 50-80% of type 1 diabetes patients need more treatment options in order to reach the treatment goal of HbA1c level lower than 7.5% Sanofi hopes to provide children and adolescent patients with an additional treatment option in order to achieve individualized treatment and better control of the disease " reference material: [1] Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes Retrieved Nov 4, 2019, from http://www.news.sanofi.us/2019-11-04-Positive-results-in-Phase-3-trial-for-Toujeo-R-in-children-and-adolescents-with-type-1-diabetes [2] A summary of recent progress in diabetes research (No 48) Retrieved Nov 4, 2019, from https://med.sina.com/article'detail'103'2'40398.html A kind of